Rosuvastatin protects against oxidized low‑density lipoprotein‑induced endothelial cell injury of atherosclerosis in vitro

Geng,Jianan; Xu,Huali; Yu,Xiaofeng; Xu,Guoliang; Cao,Hongyan; Lin,Guangzhu; Sui,Dayun

doi:10.3892/mmr.2018.9666

Rosuvastatin protects against oxidized low‑density lipoprotein‑induced endothelial cell injury of atherosclerosis in vitro

Authors:
- Jianan Geng
- Huali Xu
- Xiaofeng Yu
- Guoliang Xu
- Hongyan Cao
- Guangzhu Lin
- Dayun Sui
View Affiliations

Affiliations: Department of Pharmacology, College of Pharmacy, Jilin University, Changchun, Jilin 130021, P.R. China, Department of Cardiovascular Medicine, The Eastern Division of First Hospital, Jilin University, Changchun, Jilin 130031, P.R. China
Published online on: November 19, 2018 https://doi.org/10.3892/mmr.2018.9666
Pages: 432-440
Copyright: © Geng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Atherosclerosis‑induced cardiovascular diseases (CVDs) are accompanied by substantial morbidity and mortality. The loss and injury of endothelial cells is the primary cause of atherosclerosis. Rosuvastatin is an alternative agent used to reduce the risk of cardiovascular disease. Subsequently, the present study aimed to investigate the protective effects of rosuvastatin on oxidized‑low‑density lipoprotein (ox‑LDL)‑induced human umbilical vein endothelial cell (HUVEC) injury. The viability of ox‑LDL‑cultured HUVECs with or without rosuvastatin (0.01, 0.1 and 1 µmol/l) pretreatment, and pretreatment at different time points (3, 6, 12 and 24 h) was determined using an MTT assay. Morphological changes and the extent of apoptosis were detected; the anti‑oxidase activity, including superoxide dismutase (SOD) and catalase (CAT), was examined, and the contents of malondiahdehyde (MDA) and nitric oxide (NO) were measured. The phosphorylation levels of endothelial nitric oxide synthase (eNOS), protein kinase B (Akt) and phosphoinositide 3 kinase (PI3K) were detected using western blot analysis. The results demonstrated that pretreatment with 0.01‑1 µmol/l rosuvastatin decreased cell apoptosis caused by ox‑LDL. Notably, pretreatment with 1 µmol/l rosuvastatin for >12 h increased cell viability. Additionally, DAPI staining revealed that rosuvastatin inhibited HUVEC apoptosis. Rosuvastatin treatment also resulted in increased SOD and CAT activities and decreased MDA content in ox‑LDL‑stimulated HUVECs. Furthermore, pretreatment with 0.01‑1 µmol/l rosuvastatin significantly increased` the NO content compared with HUVECs treated with ox‑LDL alone. Western blot analyses demonstrated that rosuvastatin upregulated the phosphorylation of eNOS, Akt and PI3K. These findings indicated that rosuvastatin could protect HUVECs against ox‑LDL‑induced injury through its anti‑oxidant effect and its ability to upregulate the expression of vascular endotheliocyte‑protecting factors.

View Figures

View References

1	Samadi S, Bozorgmanesh M, Khalili D, Momenan A, Sheikholeslami F, Azizi F and Hadaegh F: Hypertriglyceridemic waist: The point of divergence for prediction of CVD vs. mortality: Tehran Lipid and Glucose Study. Int J Cardiol. 165:260–265. 2013. View Article : Google Scholar : PubMed/NCBI
2	Wong MC, Zhang DX and Wang HH: Rapid emergence of atherosclerosis in Asia: A systematic review of coronary atherosclerotic heart disease epidemiology and implications for prevention and control strategies. Curr Opin Lipidol. 26:257–269. 2015. View Article : Google Scholar : PubMed/NCBI
3	Gkaliagkousi E, Gavriilaki E, Triantafyllou A and Douma S: Clinical significance of endothelial dysfunction in essential hypertension. Curr Hypertens Rep. 17:852015. View Article : Google Scholar : PubMed/NCBI
4	Lucia J, Lucia M, Lucia J, Janicko M, Fedacko J, Novakova B, Chmelarova A, Majernik J and Pella D: Effect of ivabradine on endothelial function in patients with stable angina pectoris: Assessment with the Endo-PAT 2000 device. Adv Ther. 32:962–970. 2015. View Article : Google Scholar : PubMed/NCBI
5	Shaw J and Anderson T: Coronary endothelial dysfunction in non-obstructive coronary artery disease: Risk, pathogenesis, diagnosis and therapy. Vasc Med. 21:146–155. 2016. View Article : Google Scholar : PubMed/NCBI
6	Gu X, Yang X, Li Y, Cao J, Li J, Liu X, Chen J, Shen C, Yu L, Huang J and Gu D: Usefulness of low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as predictors of cardiovascular disease in Chinese. Am J Cardiol. 116:1063–1070. 2015. View Article : Google Scholar : PubMed/NCBI
7	Kuhlencordt PJ, Padmapriya P, Rützel S, Schödel J, Hu K, Schäfer A, Huang PL, Ertl G and Bauersachs J: Ezetimibe potently reduces vascular inflammation and arteriosclerosis in eNOS-deficient ApoE ko mice. Atherosclerosis. 202:48–57. 2009. View Article : Google Scholar : PubMed/NCBI
8	Li H, Horke S and Förstermann U: Vascular oxidative stress, nitric oxide and atherosclerosis. Atherosclerosis. 237:208–219. 2014. View Article : Google Scholar : PubMed/NCBI
9	Frostegård J: Immunity, atherosclerosis and cardiovascular disease. BMC Med. 11:1172013. View Article : Google Scholar : PubMed/NCBI
10	van Diepen JA, Berbée JF, Havekes LM and Rensen PC: Interactions between inflammation and lipid metabolism: Relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis. Atherosclerosis. 228:306–315. 2013. View Article : Google Scholar : PubMed/NCBI
11	Mitra S, Khaidakov M, Lu J, Ayyadevara S, Szwedo J, Wang XW, Chen C, Khaidakov S, Kasula SR, Stone A, et al: Prior exposure to oxidized low-density lipoprotein limits apoptosis in subsequent generations of endothelial cells by altering promoter methylation. Am J Physiol Heart Circ Physiol. 301:H506–H513. 2011. View Article : Google Scholar : PubMed/NCBI
12	Abeyrathna P and Su Y: The critical role of Akt in cardiovascular function. Vascul Pharmacol. 74:38–48. 2015. View Article : Google Scholar : PubMed/NCBI
13	Yu H, Littlewood T and Bennett M: Akt isoforms in vascular disease. Vascul Pharmacol. 71:57–64. 2015. View Article : Google Scholar : PubMed/NCBI
14	Jones SP, Gibson MF, Rimmer DM III, Gibson TM, Sharp BR and Lefer DJ: Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol. 40:1172–1178. 2002. View Article : Google Scholar : PubMed/NCBI
15	Zhang Y, Wang SJ, Han ZH, Li YQ, Xue JH, Gao DF, Wu XS and Wang CX: PI3K/AKT signaling pathway plays a role in enhancement of eNOS activity by recombinant human angiotensin converting enzyme 2 in human umbilical vein endothelial cells. Int J Clin Exp Pathol. 7:8112–8117. 2014.PubMed/NCBI
16	Aggarwal RK and Showkathali R: Rosuvastatin calcium in acute coronary syndromes. Expert Opin Pharmacother. 14:1215–1227. 2013. View Article : Google Scholar : PubMed/NCBI
17	Qian C, Wei B, Ding J, Wu H, Cai X, Li B and Wang Y: Meta-analysis comparing the effects of rosuvastatin versus atorvastatin on regression of coronary atherosclerotic plaques. Am J Cardiol. 116:1521–1526. 2015. View Article : Google Scholar : PubMed/NCBI
18	Takayama T, Komatsu S, Ueda Y, Fukushima S, Hiro T, Hirayama A and Saito S: ALTAIR study group: Comparison of the effect of rosuvastatin 2.5 mg vs. 20 mg on coronary plaque determined by angioscopy and intravascular ultrasound in Japanese with stable angina pectoris (from the Aggressive Lipid-Lowering Treatment Approach Using Intensive Rosuvastatin for Vulnerable Coronary Artery Plaque [ALTAIR] Randomized Trial). Am J Cardiol. 117:1206–1212. 2016. View Article : Google Scholar : PubMed/NCBI
19	Kurtoglu E, Balta S, Sincer I, Altas Y, Atas H, Yilmaz M, Korkmaz H, Erdem K, Akturk E, Demirkol S and Can C: Comparision of effects of rosuvastatin versus atorvastatin treatment on plasma levels of asymmetric dimethylarginine in patients with hyperlipidemia having coronary artery disease. Angiology. 65:788–793. 2014. View Article : Google Scholar : PubMed/NCBI
20	Castellon X and Bogdanova V: Chronic inflammatory diseases and endothelial dysfunction. Aging Dis. 7:81–89. 2016. View Article : Google Scholar : PubMed/NCBI
21	Byfield FJ, Rothblat GH, Gooch KJ and Levitan I: OxLDL increases endothelial stiffness, force generation and network formation. Vascul Pharmacol. 45:e732006. View Article : Google Scholar
22	Ananthakrishnan S and Kaysen GA: Treatment of hyperlipidemia changes with level of kidney function-rationale. Adv Chronic Kidney Dis. 23:247–254. 2016. View Article : Google Scholar : PubMed/NCBI
23	Xing Y, Lai J, Liu X, Zhang N, Ming J, Liu H and Zhang X: Netrin-1 restores cell injury and impaired angiogenesis in vascular endothelial cells upon high glucose by PI3K/AKT-eNOS. J Mol Endocrinol. 58:167–177. 2017. View Article : Google Scholar : PubMed/NCBI
24	Haendeler J, Weiland U, Zeiher AM and Dimmeler S: Effects of redox-related congeners of NO on apoptosis and caspase-3 activity. Nitric Oxide. 1:282–293. 1997. View Article : Google Scholar : PubMed/NCBI
25	Frank S, Kämpfer H, Wetzler C and Pfeilschifter J: Nitric oxide drives skin repair: Novel functions of an established mediator. Kidney Int. 61:882–888. 2002. View Article : Google Scholar : PubMed/NCBI
26	Vulesevic B, McNeill B, Giacco F, Maeda K, Blackburn NJ, Brownlee M, Milne RW and Suuronen EJ: Methylglyoxal-induced endothelial cell loss and inflammation contribute to the development of diabetic cardiomyopathy. Diabetes. 65:1699–1713. 2016. View Article : Google Scholar : PubMed/NCBI
27	Zhang Y, Ma KL, Liu J, Wu Y, Hu ZB, Liu L, Lu J, Zhang XL and Liu BC: Inflammatory stress exacerbates lipid accumulation and podocyte injuries in diabetic nephropathy. Acta Diabetol. 52:1045–1056. 2015. View Article : Google Scholar : PubMed/NCBI
28	Konishi H, Miyauchi K, Shitara J, Endo H, Wada H, Doi S, Naito R, Tsuboi S, Ogita M, Dohi T, et al: Impact of lipoprotein(a) on long-term outcomes in patients with diabetes mellitus who underwent percutaneous coronary intervention. Am J Cardiol. 118:1781–1785. 2016. View Article : Google Scholar : PubMed/NCBI
29	Yang X, Li Y, Li Y, Ren X, Zhang X, Hu D, Gao Y, Xing Y and Shang H: Oxidative stress-mediated atherosclerosis: Mechanisms and therapies. Front Physiol. 8:6002017. View Article : Google Scholar : PubMed/NCBI
30	Desjardins F and Balligand JL: Nitric oxide-dependent endothelial function and cardiovascular disease. Acta Clin Belg. 61:326–334. 2006. View Article : Google Scholar : PubMed/NCBI
31	Guo J, Breen DM, Pereira TJ, Dalvi PS, Zhang H, Mori Y, Ghanim H, Tumiati L, Fantus IG, Bendeck MP, et al: The effect of insulin to decrease neointimal growth after arterial injury is endothelial nitric oxide synthase-dependent. Atherosclerosis. 241:111–120. 2015. View Article : Google Scholar : PubMed/NCBI
32	Ahsan A, Han G, Pan J, Liu S, Padhiar AA, Chu P, Sun Z, Zhang Z, Sun B, Wu J, et al: Phosphocreatine protects endothelial cells from oxidized low-density lipoprotein-induced apoptosis by modulating the PI3K/Akt/eNOS pathway. Apoptosis. 20:1563–1576. 2015. View Article : Google Scholar : PubMed/NCBI
33	Valentino M, Al Danaf J, Panakos A, Ragupathi L, Duffy D and Whellan D: Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke. Am Heart J. 181:130–136. 2016. View Article : Google Scholar : PubMed/NCBI
34	O'Keefe JH, DiNicolantonio JJ and Lavie CJ: Statins, ezetimibe, and proprotein convertase subtilisin-kexin Type 9 inhibitors to reduce low-density lipoprotein cholesterol and cardiovascular events. Am J Cardiol. 119:565–571. 2017. View Article : Google Scholar : PubMed/NCBI
35	Dong Y, Fernandes C, Liu Y, Wu Y, Wu H, Brophy ML, Deng L, Song K, Wen A, Wong S, et al: Role of endoplasmic reticulum stress signalling in diabetic endothelial dysfunction and atherosclerosis. Diab Vasc Dis Res. 14:14–23. 2017. View Article : Google Scholar : PubMed/NCBI